Correspondence 0001493152-24-014376 from bioAffinity Technologies, Inc. (BIAF)
bioAffinity Technologies, Inc.
Date: April 11, 2024 · CIK: 0001712762 · Accession: 0001493152-24-014376
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-278512
Letter
VIA EDGAR United States Securities Division of Corporation Finance Attention: Benjamin Richie bioAffinity Technologies, Inc. Registration Statement on Form S-1 Filed April 4, 2024 File No: 333-278512
Dear Mr. Richie:
bioAffinity Technologies, Inc. (the “Registrant”) hereby requests that the effective date of the above-referenced Registration Statement on Form S-1 (File No. 333-278512), be accelerated by the U.S. Securities and Exchange Commission (the “Commission”) to become effective on Monday, April 15, 2024, at 5:00 p.m., Eastern Time, or as soon as reasonably practicable thereafter.
The Registrant understands that the Staff of the Commission will consider this request as confirmation by the Registrant that it is aware of its responsibilities under the federal securities laws as they relate to the issuance of the securities covered by the Registration Statement.
The Registrant hereby authorizes Leslie Marlow of Blank Rome LLP to orally modify or withdraw this request for acceleration. Please contact Ms. Marlow at (516) 457-4238 with any questions you may have concerning this request, and please notify either of them when this request for acceleration has been granted.
Very
truly yours,
BIOAFFINITY
TECHNOGIES, INC.
Show Raw Text
CORRESP
1
filename1.htm
April
11, 2024
VIA
EDGAR
United
States Securities
and
Exchange Commission
Division
of Corporation Finance
100
F Street, N.E.
Washington,
D.C. 20549
Attention:
Benjamin Richie
Re:
bioAffinity
Technologies, Inc.
Registration
Statement on Form S-1
Filed
April 4, 2024
File
No: 333-278512
Dear
Mr. Richie:
bioAffinity
Technologies, Inc. (the “Registrant”) hereby requests that the effective date of the above-referenced Registration
Statement on Form S-1 (File No. 333-278512), be accelerated by the U.S. Securities and Exchange Commission (the “Commission”)
to become effective on Monday, April 15, 2024, at 5:00 p.m., Eastern Time, or as soon as reasonably practicable thereafter.
The
Registrant understands that the Staff of the Commission will consider this request as confirmation by the Registrant that it is aware
of its responsibilities under the federal securities laws as they relate to the issuance of the securities covered by the Registration
Statement.
The
Registrant hereby authorizes Leslie Marlow of Blank Rome LLP to orally modify or withdraw this request for acceleration. Please contact
Ms. Marlow at (516) 457-4238 with any questions you may have concerning this request, and please notify either of them when this request
for acceleration has been granted.
Very
truly yours,
BIOAFFINITY
TECHNOGIES, INC.
By:
/s/
Maria Zannes
Name:
Maria
Zannes
Title:
Chief
Executive Officer
cc:
Leslie Marlow, Blank Rome LLP